Blue Horseshoe Stocks: Form-4 Watchlist, Options Ideas & More

Insider Buying Watchlist

Both of the following are plays that we’ve tracked in some capacity in the past, and each of them grabbed our attention with recent insider transactions of a sizable magnitude which were executed at higher levels than the current PPS. We like to monitor stocks whose directors have confidence in future price performance, and that’s the impression we get when they soak up large blocks of shares in this manner. Each of these stocks is also currently trading at a relative bottom, so we’ll be watching in the days and weeks to come for signs of bounceplay opportunities. 

The ExOne Co.  XONE

In the case of XONE, CEO Kent Rockwell last weekend filed a Form-4 indicating the purchase of a $13M block of XONE at 9.13, more than a dollar per share higher than the current PPS. This is a significant development that warrants heavy monitoring for XONE.

Esperion Therapeutics, Inc. ESPR

The traunch of shares purchased by ESPR director Tim Mayleben wasn’t nearly as large as the previously mentioned block, but still, a $100K investment is nothing at which to sneeze. The trade was executed at 14.08 (Current PPS:13.77). ESPR has just come up off of its newly established 52-week lows, and has been going through a bout of serious under-performance, so we’ll want to keep our heads on a swivel for any developments that might kick this thing into gear.

Fresh Options Ideas

To kick things off this week on the options front, we’ve formulated a couple of ideas based on announced and expected earnings, and the resultant activity we’re observing here in the premarket.

Tiffany & Co. TIF

We’re looking at going bearish on TIF, which, on the heels of a lackluster holiday season in terms of jewelry sales, failed to meet or beat earnings expectations and is currently gapping down in early trading. We’re going to track a range of contracts here, namely the TIF Weekly $66.50-64 Puts, for potential daytrades.

Netflix, Inc. NFLX

NFLX has its earnings call slated for the post-market today, and we’re going to want to track a range of calls in anticipation of that event. We’ve witnessed runs into earnings so many times before, it’d almost be foolish to ignore NFLX under the present circumstances. We’re going to keep an eye on NFLX Weekly $105-107 Calls to take advantage of a possible continued run-up for the stock.

Extended Watchlist:
SBS, AEZS, SHOP, COTE, GDPM, BVAP, PLKD(Bottom-Watch), FREE(1-for-60 Reverse Split)

Blue Horseshoe Stocks: Potential Bottom-Plays & More

Solaris Power Cells, Inc. SPCL

We’ve got a news play hitting our scanner this morning in SPCL, and as it turns out, the chart is looking ripe for a nice move. As we’ve pointed out on the following snapshot, the stock is trading near a relative bottom, having just registered a new 52-week low just two weeks ago.

Our regular readers are well acquainted with our history of banking excellent gains off a good rebound play. SPCL could be next in line on that front, so we’ll keep a sharp eye on it to start the week.

In addition to trading near a bottom, we’re seeing signs of a very oversold stock with a lot of room to the upside:

PALM SPRINGS, Calif., July 13, 2015 (GLOBE NEWSWIRE) — Solaris Power Cells, Inc. the creators of the Solaris PESATM “Passive Electron Storage Array”™, (the “Company”) (OTCQB:SPCL)  the Board of Directors of Solaris Power Cells today announced the appointment of long-time energy policy leader Robert Foster to lead Solaris Energy Storage Advisory Board, effective July 10th 2015. >> FULL PR

OncoGenex Pharmaceuticals, Inc OGXI

OGXI announced this morning that one of its cancer treatments, currently in Phase III trials has passed rigorous criteria and
that trials for patients with non-small cell lung cancer will proceed as planned. The stock is gapping up in premarket trading, and we’re going to monitor its activity as the session commences.

BOTHELL, Wash. and VANCOUVER, British Columbia, July 13, 2015 /PRNewswire/ — OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that its Phase 3 ENSPIRIT trial evaluating custirsen in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) is continuing as planned per the recommendation of an Independent Data Monitoring Committee>> FULL PR

Frontline, Ltd. FRO

We’ve got a long history with FRO that stretches all the way back to 2012. We tagged FRO in Thursday’s premarket report, after it hit a relative bottom of 2.21 on Wednesday. Our observed low following Thursday’s alert was 2.32, and on Friday we saw as the stock inched up to a high of 2.43. We’re going to be on the lookout for further gains; the stock is gapping up slightly in early trading this morning.

An added element to the story is an opinion article that came across the wires last week pertaining to the perceived undervaluation of FRO. It points to a potential longer-term uptrend in the cards, stating that while this year’s earnings growth is expected to top last year’s by more than 200%, that hasn’t really been reflected in the share price. We suggest our subscribers click the following link and give it a read >> VIEW ARTICLE

Extended Watchlist:

Blue Horseshoe Stocks: Fresh News Plays & More

FreeSeas, Inc. FREE

We mentioned FREE in yesterday’s morning report as a bottom-play that was gaining momentum. The stock had begun to show signs of life after recently establishing a new 52-week low, and our focus paid off almost instantly.

We witnessed a slight dip to a low of .1113 shortly before 10AM, after which time FREE proceeded to surge its way to a daily high of .179. It registered as a 61% intraday swing before the stock tapered back to close at .091.

We’ll continue to observe the activity on the FREE chart as the week progresses, as there is a fair chance that we will continue to see sizable swings in PPS.

Axion Power International, Inc. AXPW

Speaking of major runners, the call we made on AXPW on Monday continued to extend its gains early in yesterday’s session. We caught this gem at a low of .0421, and watched as it went on to touch .36 before it began its pullback.

The move extended the total range we witnessed over just a two-session span to a whopping 755%

For us to remain interested in AXPW for further opportunities, we’ll need to see it maintain support at or above yesterday’s swing low of .14. Key resistance is sitting between .18-19.

Fresh News Plays

Synergy Pharmaceutical, Inc. SGYP
came with some positive news this morning, and is gapping up heavily in the premarket. We’ll look for a potential dip-and-rip scenario to occur following the opening bell.


Blue Shere Corp. BLSP announced a tentative share buyback program this morning that would allow for the company to acquire up to $500K-worth of its common stock from the open market and/or via privately arranged transactions. Couple that with a chart that has the look of a classic bottom-play, and we’re very interested to include BLSP on our watchlist this midweek.

Extended Watchlist: